You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

KRAS Mutant Advanced Non-Small Cell Lung Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

Not yet recruiting
  • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
  • New York, New York
    NYU Langone Health
Apr 4, 2023

Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

Not yet recruiting
  • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
  • New York, New York
    NYU Langone Health
Apr 4, 2023

NSCLC, KRAS Mutation-Related Tumors Trial in Philadelphia (Binimetinib Pill, Hydroxychloroquine Pill)

Recruiting
  • Non-Small Cell Lung Cancer
  • KRAS Mutation-Related Tumors
  • Binimetinib Pill
  • Hydroxychloroquine Pill
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Sep 30, 2022

Non Small Cell Lung Cancer, KRAS Gene Mutation Trial in United States (Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG)

Completed
  • Non Small Cell Lung Cancer
  • KRAS Gene Mutation
  • Trametinib 0.5 mg
  • +5 more
  • Basking Ridge, New Jersey
  • +6 more
Feb 7, 2022

NSCLC (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors Trial in Irving, San Antonio,

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors
  • Assigned interventions
  • Irving, Texas
  • +2 more
Nov 7, 2023

NSCLC Trial in Baltimore (Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
  • Baltimore, Maryland
    Johns Hopkins University
Jun 16, 2022

Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer Trial in United States (VS-6766 and adagrasib)

Recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • avutometinib (VS-6766) and adagrasib
  • San Francisco, California
  • +4 more
Dec 21, 2022

KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, NSCLC Trial (JDQ443, trametinib, Ribociclib)

Recruiting
  • KRAS G12C Mutant Solid Tumors
  • +10 more
  • Boston, Massachusetts
  • +5 more
Jan 11, 2023

Non Small Cell Lung Cancer Trial in Nashville (AMG 510, MVASI)

Recruiting
  • Non Small Cell Lung Cancer
  • Nashville, Tennessee
    Vanderbilt Ingram Cancer Center
Jun 28, 2022

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,

Recruiting
  • Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
  • +2 more
  • Futibatinib and Binimetinib
  • Santa Monica, California
  • +2 more
Jun 2, 2022

Non Small Cell Lung Cancer Trial in Shanghai (Trametinib, Anlotinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Jan 16, 2022

Lung Cancer Trial in Boston (Binimetinib, Palbociclib)

Recruiting
  • Lung Cancer
  • Boston, Massachusetts
  • +1 more
Jan 18, 2022

NSCLC Trial in Worldwide (JDQ443, docetaxel)

Recruiting
  • Non-Small Cell Lung Cancer
  • Caba, Buenos Aires, Argentina
  • +34 more
Dec 19, 2022

KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma

Active, not recruiting
  • KRAS Gene Mutation
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Nov 1, 2021

Advanced NSCLC Trial in Miami, New York, Allentown (RO5126766)

Active, not recruiting
  • Advanced Non-small Cell Lung Cancer
  • Miami, Florida
  • +2 more
Dec 1, 2021

Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in Worldwide (VS-6766, VS-6766 and Defactinib)

Recruiting
  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation
  • avutometinib (VS-6766)
  • avutometinib (VS-6766) and Defactinib
  • Duarte, California
  • +44 more
Dec 22, 2022

NSCLC Trial in United States (VIC-1911, sotorasib)

Recruiting
  • Non-small Cell Lung Cancer
  • Sacramento, California
  • +4 more
Jan 5, 2023

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

NSCLC (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) Trial in San Antonio, Fairfax (RMC-9805)

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +3 more
  • San Antonio, Texas
  • +1 more
Sep 8, 2023

NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

Not yet recruiting
  • NSCLC
  • Non-small Cell Lung Cancer
  • Apatinib + Fluzoparib
  • Apatinib + Fluzoparib + Adebrelimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 27, 2023

KRAS G12C Mutant Solid Tumors, NSCLC, Carcinoma, Colorectal Trial in Worldwide (JDQ443, TNO155, tislelizumab)

Recruiting
  • KRAS G12C Mutant Solid Tumors
  • +9 more
  • Atlanta, Georgia
  • +31 more
Jul 7, 2022

KRAS Gene Mutation Trial in Cincinnati, Dallas (TVB-2640)

Recruiting
  • KRAS Gene Mutation
  • Cincinnati, Ohio
  • +1 more
Dec 19, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 2, 2023

NSCLC, Melanoma Trial in Worldwide (LXH254, LTT462, Trametinib)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Melanoma
  • San Diego, California
  • +31 more
Sep 12, 2022

NSCLC Trial in Busan (GDC-6036, Pembrolizumab)

Recruiting
  • Non-Small Cell Lung Cancer
  • Busan, Korea, Republic of
    Pusan National University Hospital
Apr 3, 2023